XTX Topco Ltd Has $409,000 Stock Holdings in Guardant Health, Inc. (NASDAQ:GH)

XTX Topco Ltd reduced its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 49.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 17,833 shares of the company's stock after selling 17,325 shares during the quarter. XTX Topco Ltd's holdings in Guardant Health were worth $409,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its position in shares of Guardant Health by 188.6% during the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company's stock worth $232,325,000 after purchasing an additional 6,618,785 shares during the last quarter. Eventide Asset Management LLC lifted its holdings in shares of Guardant Health by 2.0% during the third quarter. Eventide Asset Management LLC now owns 3,837,300 shares of the company's stock worth $88,028,000 after buying an additional 76,762 shares during the last quarter. ARK Investment Management LLC boosted its position in shares of Guardant Health by 233.5% in the third quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company's stock valued at $34,701,000 after acquiring an additional 1,059,104 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Guardant Health by 31.8% in the second quarter. Bank of New York Mellon Corp now owns 1,280,221 shares of the company's stock worth $36,973,000 after acquiring an additional 309,157 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in Guardant Health by 1,282.5% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company's stock worth $28,128,000 after acquiring an additional 1,137,482 shares during the period. Institutional investors own 92.60% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on GH shares. Sanford C. Bernstein cut their target price on shares of Guardant Health from $40.00 to $35.00 and set an "outperform" rating for the company in a research note on Wednesday, October 30th. UBS Group upped their price objective on shares of Guardant Health from $32.00 to $40.00 and gave the company a "buy" rating in a research report on Wednesday, August 21st. The Goldman Sachs Group lifted their target price on Guardant Health from $32.00 to $36.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. upped their price target on Guardant Health from $48.00 to $50.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Finally, Leerink Partners reduced their price objective on Guardant Health from $60.00 to $50.00 and set an "outperform" rating for the company in a research report on Thursday, October 17th. Fifteen analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $40.60.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the company's stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the transaction, the director now owns 2,676 shares of the company's stock, valued at approximately $93,660. This represents a 46.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Meghan V. Joyce sold 2,896 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the transaction, the director now owns 7,648 shares in the company, valued at $228,675.20. The trade was a 27.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,316 shares of company stock valued at $171,380 in the last three months. 5.50% of the stock is owned by corporate insiders.

Guardant Health Price Performance

Guardant Health stock traded up $0.86 during mid-day trading on Monday, hitting $35.62. 1,839,591 shares of the company were exchanged, compared to its average volume of 2,038,397. The company has a market capitalization of $4.40 billion, a PE ratio of -8.40 and a beta of 1.26. The business has a fifty day moving average of $28.21 and a 200 day moving average of $28.21. Guardant Health, Inc. has a 1-year low of $15.81 and a 1-year high of $38.53. The company has a quick ratio of 5.85, a current ratio of 6.22 and a debt-to-equity ratio of 16.70.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.33). The firm had revenue of $191.48 million for the quarter, compared to analyst estimates of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The company's revenue for the quarter was up 33.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.73) EPS. As a group, sell-side analysts expect that Guardant Health, Inc. will post -3.44 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.